Skip to main content

Chance Pharma Completes $30 Million Round for Inhalation Therapies

Chance Pharma of Hangzhou, an inhalation therapy company, completed a $30 million Series C financing led by new investor Lapam Capital. Chance intends to use the capital to advance its R&D, start new business collaborations and accelerate the construction of a manufacturing facility. Also participating in the C round were new investors CMS Capital and HEDA BioVenture and existing investor Guozhong Capital. Earlier this year, Chance signed a deal with Aerami Therapeutics to acquire greater  China  rights for a drug device combination product aimed at Pulmonary Arterial Hypertension. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.